TFF Pharmaceuticals announces update on clinical program

TFF Pharmaceuticals is announcing data updates and strategic prioritization of its clinical programs. Based on positive data from the ongoing Phase 2 study of TFF TAC, the potential to address a significant unmet need in lung transplant medicine, and substantial market opportunity, the Company has made the decision to prioritize the TFF TAC program and focus resources on the acceleration of its clinical pathway towards registration. “For decades, legacy immunosuppressive drugs such as IV and oral tacrolimus, while effective in preventing acute rejection, have resulted in an unacceptable level of systemic toxicities, which has created constant challenges in maintaining the overall health of the transplant recipient,” said Zamaneh Mikhak, M.D., Chief Medical Officer of TFF Pharmaceuticals. “Based on our Phase 2 data and the overwhelmingly positive feedback that we have received from KOL and clinical investigators, we believe that TFF TAC has the potential to introduce a groundbreaking advancement in the delivery of immunosuppressive therapy that will overcome these limitations and fundamentally change how these life-saving medicines are delivered to patients. We have therefore made the decision to prioritize the TFF TAC program with the aim of accelerating its clinical development pathway toward registration, and we look forward to discussing updated data from our Phase 2 program.”